| VERRICA PHARMACEUTICALS |
| USA |
| Gesundheit |
| US92511W2070 / A41A98 |
| 1NE0 (Frankfurt) / VRCA (NASDAQ) |
| FRA:1NE0, ETR:1NE0, 1NE0:GR, NASDAQ:VRCA |
| - |
| https://verrica.com/ |
|
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States. The company's primary product is YCANTH (VP-102), a drug-device combination featuri..
>Volltext.. |
| 73.8 Mio. EUR |
| 65.61 Mio. EUR |
| 26.21 Mio. EUR |
| -22.18 Mio. EUR |
| -26.95 Mio. EUR |
| -1.45 EUR |
| 1.56 Mio. EUR |
| 9.68 Mio. EUR |
| -11.63 Mio. EUR |
| 0.5 |
| 112.7% |
| 33.82% |
| - |
| - |
| - |
| VERRICA |
| 19.08.26 |